EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted therapies in children with renal cell carcinoma ( RCC ): An International Society of Pediatric Oncology—Renal Tumor Study Group ( SIOP‐RTSG )‐related retrospective descriptive study

Julia Sprokkerieft iD, Justine N van der Beek iD, Filippo Spreafico, Barbara Selle, Estelle Thebaud, Tanzina Chowdhury, Jesper Brok, Gábor Ottóffy, Xiaofei Sun, Gema L Ramírez Villar, Garik Sagoyan iD, Heidi Segers und 7 weitere

Cancer Medicine · 2024-01 · 13 (1)

DOI: 10.1002/cam4.6782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 22.12.2023. Verfasst von Julia Sprokkerieft und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Introduction: Renal cell carcinoma (RCC) is a very rare pediatric renal tumor. Robust evidence to guide treatment is lacking and knowledge on targeted therapies and immunotherapy is mainly based on adult studies. Currently, the International Society of Pediatric Oncology–Renal Tumor Study Group (SIOP‐RTSG) 2016 UMBRELLA protocol recommends sunitinib for metastatic or unresectable RCC.

Methods

This retrospective study describes the effects of tyrosine kinase inhibitors (TKI), anti‐programmed cell death 1 (PD‐(L)1) monoclonal antibodies, and immunotherapeutic regimens in advanced‐stage and relapsed pediatric RCC.

Results

Of the 31 identified patients (0–18 years) with histologically proven RCC, 3/31 presented with TNM stage I/II, 8/31 with TNM stage III, and 20/31 with TNM stage IV at diagnosis. The majority were diagnosed with translocation type RCC (MiT‐RCC) (21/31) and the remaining patients mainly presented with papillary or clear‐cell RCC. Treatment in a neoadjuvant or adjuvant setting, or upon relapse or progression, included mono‐ or combination therapy with a large variety of drugs, illustrating center specific choices in most patients. Sunitinib was often administered as first choice and predominantly resulted in stable disease (53%). Other frequently used drugs included axitinib, cabozantinib, sorafenib, and nivolumab; however, no treatment seemed more promising than sunitinib. Overall, 15/31 patients died of disease, 12/31 are alive with active disease, and only four patients had a complete response. The sample size and heterogeneity of this cohort only allowed descriptive statistical analysis.

Conclusion

This study provides an overview of a unique series of clinical and treatment characteristics of pediatric patients with RCC treated with targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansChildRetrospective StudiesMaleFemaleAdolescentChild, PreschoolInfantMolecular Targeted TherapySunitinibProtein Kinase InhibitorsInfant, NewbornAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsNeoplasm Staging

Stichwörter der Autor:innen

MiT family translocationpediatricrenal cell carcinomatargeted therapytreatment response

Substanzen

SunitinibProtein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Pediatric Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Hopp Children's Cancer Center Heidelberg (KiTZ) & Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Hôtel Dieu, CHU de Nantes, Nantes, France.
  • Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Department of Pediatric Hematology and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

ORCID-Profile: Julia Sprokkerieft, Justine N van der Beek, Garik Sagoyan, Lauriane Lemelle

Zitieren

APA

Sprokkerieft, J., van der Beek, J. N., Spreafico, F., Selle, B., Thebaud, E., Chowdhury, T., Brok, J., Ottóffy, G., Sun, X., Ramírez Villar, G. L., Sagoyan, G., Segers, H., Doganis, D., Serra, A., Lemelle, L., Graf, N., Verschuur, A. C., Tytgat, G. A. M., & van den Heuvel-Eibrink, M. M. (2024). Targeted therapies in children with renal cell carcinoma ( RCC ): An International Society of Pediatric Oncology—Renal Tumor Study Group ( SIOP‐RTSG )‐related retrospective descriptive study. Cancer Medicine, 13(1). https://doi.org/10.1002/cam4.6782

Vancouver

Sprokkerieft J, van der Beek JN, Spreafico F, Selle B, Thebaud E, Chowdhury T, et al. Targeted therapies in children with renal cell carcinoma ( RCC ): An International Society of Pediatric Oncology—Renal Tumor Study Group ( SIOP‐RTSG )‐related retrospective descriptive study. Cancer Medicine. 2024;13(1). doi:10.1002/cam4.6782

BibTeX
@article{Sprokkerieft2024,
  author = {Sprokkerieft, Julia and van der Beek, Justine N and Spreafico, Filippo and Selle, Barbara and Thebaud, Estelle and Chowdhury, Tanzina and Brok, Jesper and Ottóffy, Gábor and Sun, Xiaofei and Ramírez Villar, Gema L and Sagoyan, Garik and Segers, Heidi and Doganis, Dimitrios and Serra, Annalisa and Lemelle, Lauriane and Graf, Norbert and Verschuur, Arnauld C and Tytgat, Godelieve A M and van den Heuvel-Eibrink, Marry M},
  title = {Targeted therapies in children with renal cell carcinoma ( RCC ): An International Society of Pediatric Oncology—Renal Tumor Study Group ( SIOP‐RTSG )‐related retrospective descriptive study},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {1},
  doi = {10.1002/cam4.6782}
}
Kostenlos starten →